PCM
PLSE icon

Prelude Capital Management’s Pulse Biosciences PLSE Stock Holding History

Prelude Capital Management’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,340
Closed -$45K – 1879
2018
Q1 		$45K Buy
+3,340
New +$63.4K ﹤0.01% 1118

Other funds holding PLSE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCP
Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Prelude Capital Management's PLSE Position: Q2 2018 in Review

Prelude Capital Management sold out of Pulse Biosciences (PLSE) in Q2 2018, closing a stake of 3,340 shares — an estimated $45K sold.

Prelude Capital Management first reported a position in PLSE in Q1 2018 and held it in 1 quarter. The position peaked at $45K in Q1 2018. 43 funds tracked by Wall St. Rank hold PLSE as of Q2 2018.

  • Prelude Capital Management reported no remaining Pulse Biosciences position as of Q2 2018 after selling out during the quarter.
  • Prelude Capital Management sold 3,340 Pulse Biosciences shares in Q2 2018, an estimated $45K.
  • Prelude Capital Management first reported a position in Pulse Biosciences in Q1 2018 and held it in 1 quarter.
  • Prelude Capital Management's Pulse Biosciences position peaked at $45K in Q1 2018.
  • 43 funds tracked by Wall St. Rank held Pulse Biosciences as of Q2 2018.

Based on Prelude Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.